User menu

Radioimmunotherapy with radioactive nanoparticles: biological doses and treatment efficiency for vascularized tumors with or without a central hypoxic area.

Bibliographic reference Bouchat, Véronique ; Nuttens, V E ; Michiels, C. ; Masereel, Bernard ; Feron, Olivier ; et. al. Radioimmunotherapy with radioactive nanoparticles: biological doses and treatment efficiency for vascularized tumors with or without a central hypoxic area.. In: Medical Physics, Vol. 37, no. 4, p. 1826-1839 (2010)
Permanent URL
  1. Mehta Minesh, Scrimger Rufus, Mackie Rock, Paliwal Bhudatt, Chappell Rick, Fowler Jack, A new approach to dose escalation in non–small-cell lung cancer, 10.1016/s0360-3016(00)01374-2
  2. Bethge Wolfgang A., Sandmaier Brenda M., Targeted Cancer Therapy Using Radiolabeled Monoclonal Antibodies, 10.1177/153303460500400407
  3. Govindan Serengulam V., Griffiths Gary L., Hansen Hans J., Horak Ivan D., Goldenberg David M., Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies, 10.1177/153303460500400406
  4. Sharkey, J. Nucl. Med., 46, 115s (2005)
  5. Goldenberg, Cancer Immunol. Immunother, 52, 281 (2003)
  6. Bouchat V., Nuttens V. E., Lucas S., Michiels C., Masereel B., Féron O., Gallez B., Borght T. Vander, Radioimmunotherapy with radioactive nanoparticles: First results of dosimetry for vascularized and necrosed solid tumors : Monte Carlo dosimetry for radioactive nanoparticles, 10.1118/1.2791038
  7. Welch M. J., Hawker C. J., Wooley K. L., The Advantages of Nanoparticles for PET, 10.2967/jnumed.109.061846
  8. Pene Frédéric, Courtine Emilie, Cariou Alain, Mira Jean-Paul, Toward theragnostics : , 10.1097/ccm.0b013e3181921349
  9. Moghimi S. M., Nanomedicine: current status and future prospects, 10.1096/fj.04-2747rev
  10. Moghimi S.M., Szebeni J., Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties, 10.1016/s0163-7827(03)00033-x
  11. OWENSIII D, PEPPAS N, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles, 10.1016/j.ijpharm.2005.10.010
  12. Gref R, Lück M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Müller R.H, ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption, 10.1016/s0927-7765(99)00156-3
  13. Yi Yilwoong, Kim Jae Hong, Kang Hye-Won, Oh Hun Seung, Kim Sung Wan, Seo Min Hyo, A Polymeric Nanoparticle Consisting of mPEG-PLA-Toco and PLMA-COONa as a Drug Carrier: Improvements in Cellular Uptake and Biodistribution, 10.1007/s11095-004-1187-1
  14. Chen Jing, Wu Hua, Han Deyan, Xie Changsheng, Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer, 10.1016/j.canlet.2005.01.024
  15. Kaul Goldie, Amiji Mansoor, Biodistribution and Targeting Potential of Poly(ethylene glycol)-modified Gelatin Nanoparticles in Subcutaneous Murine Tumor Model, 10.1080/10611860400013451
  16. Woodward Jonathan D, Kennel Steve J, Mirzadeh Saed, Dai Sheng, Wall Jonathan S, Richey Tina, Avenell James, Rondinone Adam J, In vivoSPECT/CT imaging and biodistribution using radioactive Cd125mTe/ZnS nanoparticles, 10.1088/0957-4484/18/17/175103
  17. Kannan Raghuraman, Rahing Valerie, Cutler Cathy, Pandrapragada Ravi, Katti Kavita K., Kattumuri Vijaya, Robertson J. David, Casteel Stan J., Jurisson Silvia, Smith Charles, Boote Evan, Katti Kattesh V., Nanocompatible Chemistry toward Fabrication of Target-Specific Gold Nanoparticles, 10.1021/ja063280c
  18. Katti K. V., Kannan R., Katti K., Kattumori V., Pandrapraganda R., Rahing V., Cutler C., Boote E. J., Casteel S. W., Smith C. J., Robertson J. D., Jurrison S. S., Hybrid gold nanoparticles in molecular imaging and radiotherapy, 10.1007/s10582-006-1033-2
  19. Chanda, Nanomedicine
  20. Wu Hong, Wang Jun, Wang Zhemin, Fisher Darrell R., Lin Yuehe, Apoferritin-Templated Yttrium Phosphate Nanoparticle Conjugates for Radioimmunotherapy of Cancers, 10.1166/jnn.2008.177
  21. Dionysiou, Cancer Inform., 2, 113 (2006)
  22. Ruggieri Ruggero, Hypofractionation in non-small cell lung cancer (NSCLC): suggestions from modelling both acute and chronic hypoxia, 10.1088/0031-9155/49/20/011
  23. Levin-Plotnik D, Hamilton R J, Optimization of tumour control probability for heterogeneous tumours in fractionated radiotherapy treatment protocols, 10.1088/0031-9155/49/3/005
  24. Stabin MG, Flux GD, Internal dosimetry as a tool for radiation protection of the patient in nuclear medicine, 10.2349/biij.3.2.e28
  25. Stabin M.G., Tagesson M., Thomas S.R., Ljungberg M., Strand S.E., Radiation dosimetry in nuclear medicine, 10.1016/s0969-8043(98)00023-2
  26. Barone, J. Nucl. Med., 46, 99s (2005)
  27. Astrahan Melvin, Some implications of linear-quadratic-linear radiation dose-response with regard to hypofractionation : LQ-L implications, 10.1118/1.2969065
  28. Warkentin Brad, Stavrev Pavel, Stavreva Nadia, Field Colin, Fallone B. Gino, A TCP-NTCP estimation module using DVHs and known radiobiological models and parameter sets, 10.1120/jacmp.v5i1.1970
  29. Thirion Pierre, Holmberg Ola, Collins Conor D, O'Shea Carmel, Moriarty Michael, Pomeroy Maeve, O'Sullivan Catriona, Buckney Steve, Armstrong John, Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy, 10.1016/j.radonc.2003.09.006
  30. Kodym Elisabeth, Kodym Reinhard, Reis Aimee E., Habib Amyn A., Story Michael D., Saha Debabrata, The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells, 10.1016/j.lungcan.2008.12.026
  31. Engelsman Martijn, Damen Eugène M.F., De Jaeger Katrien, van Ingen Karel M., Mijnheer Ben J., The effect of breathing and set-up errors on the cumulative dose to a lung tumor, 10.1016/s0167-8140(01)00349-8
  32. Döme Balázs, Paku Sándor, Somlai Beáta, Tímár József, Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance : Angiogenesis of malignant melanoma, 10.1002/path.1124
  33. Beli�n Jeroen A. M., van Diest Paul J., Baak Jan P. A., Relationships between vascularization and proliferation in invasive breast cancer, 10.1002/(sici)1096-9896(199911)189:3<309::aid-path457>;2-0
  34. Schlueter Claudia, Weber Holger, Meyer Britta, Rogalla Piere, Röser Kerstin, Hauke Sven, Bullerdiek Jörn, Angiogenetic Signaling through Hypoxia, 10.1016/s0002-9440(10)62344-9
  35. Humm, J. Nucl. Med., 31, 75 (1990)
  36. Nuttens V.E., Wéra A.-C., Bouchat V., Lucas S., Determination of biological vector characteristics and nanoparticle dimensions for radioimmunotherapy with radioactive nanoparticles, 10.1016/j.apradiso.2007.08.017
  37. Atthey M, Nahum A E, Flower M A, McCready V R, Effects of cellular repair and proliferation on targeted radionuclide therapy: a modelling study, 10.1088/0031-9155/45/4/402
  38. Cremonesi, Q. J. Nucl. Med. Mol. Imaging, 50, 288 (2006)
  39. Howell Roger W., Rao Dandamudi V., Sastry Kandula S. R., Macroscopic dosimetry for radioimmunotherapy: Nonuniform activity distributions in solid tumors : Macroscopic dosimetry for radioimmunotherapy, 10.1118/1.596404
  40. Sharkey Robert M., Goldenberg David M., Use of antibodies and immunoconjugates for the therapy of more accessible cancers, 10.1016/j.addr.2008.04.011
  41. Wiseman Gregory A, White Christine A, Sparks Richard B, Erwin William D, Podoloff Donald A, Lamonica Dominick, Bartlett Nancy L, Anthony Parker J, Dunn William L, Spies Stewart M, Belanger Richard, Witzig Thomas E, Leigh Bryan R, Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, 10.1016/s1040-8428(01)00107-x
  42. Howell, J. Nucl. Med., 35, 1861 (1994)
  43. Tobinai K., Kobayashi Y., Narabayashi M., Ogura M., Kagami Y., Morishima Y., Ohtsu T., Igarashi T., Sasaki Y., Kinoshita T., Murate T., 10.1023/a:1008265313133
  44. Reynaert N., Palmans H., Thierens H., Jeraj R., Parameter dependence of theMCNPelectron transport in determining dose distributions, 10.1118/1.1508798
  45. Schaart Dennis R, Jansen Jan Th M, Zoetelief Johannes, Leege Piet F A de, A comparison of MCNP4C electron transport with ITS 3.0 and experiment at incident energies between 100 keV and 20 MeV: influence of voxel size, substeps and energy indexing algorithm, 10.1088/0031-9155/47/9/303
  46. Brans B., Bodei L., Giammarile F., Linden O., Luster M., Oyen W. J. G., Tennvall J., Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”, 10.1007/s00259-006-0338-5
  47. Dale R. G., The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy, 10.1259/0007-1285-58-690-515
  48. Dale Roger, Carabe-Fernandez Alejandro, The Radiobiology of Conventional Radiotherapy and Its Application to Radionuclide Therapy, 10.1089/cbr.2005.20.47
  49. Bodey Rachel K., Evans Phil M., Flux Glenn D., Application of the linear-quadratic model to combined modality radiotherapy, 10.1016/j.ijrobp.2003.12.031
  50. Chiesa Carlo, Botta Francesca, Di Betta Erika, Coliva Angela, Maccauro Marco, Aliberti Gianluca, Bavusi Sergio, Devizzi Liliana, Guidetti Anna, Seregni Ettore, Gianni Alessandro Massimo, Bombardieri Emilio, Dosimetry in Myeloablative90Y-Labeled Ibritumomab Tiuxetan Therapy: Possibility of Increasing Administered Activity on the Base of Biological Effective Dose Evaluation. Preliminary Results, 10.1089/cbr.2007.302
  51. Baechler Sébastien, Hobbs Robert F., Prideaux Andrew R., Wahl Richard L., Sgouros George, Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry : Extension of BED to the MIRD schema, 10.1118/1.2836421
  52. Wang Jian Z, Li X.Allen, D'Souza Warren D, Stewart Robert D, Impact of prolonged fraction delivery times on tumor control: A note of caution for intensity-modulated radiation therapy (IMRT), 10.1016/s0360-3016(03)00499-1
  53. Gordon Steel G., Deacon Judith M., Duchesne Gillian M., Horwich Alan, Kelland Lloyd R., Peacock John H., The dose-rate effect in human tumour cells, 10.1016/s0167-8140(87)80151-2
  54. Guerrero Mariana, Li X Allen, Halftime for repair of sublethal damage in normal bladder and rectum: an analysis of clinical data from cervix brachytherapy, 10.1088/0031-9155/51/16/012
  55. Dawson A., Hillen T., Derivation of the Tumour Control Probability (TCP) from a Cell Cycle Model, 10.1080/10273660600968937
  56. MATSUFUJI Naruhiro, KANAI Tatsuaki, KANEMATSU Nobuyuki, MIYAMOTO Tadaaki, BABA Masayuki, KAMADA Tadashi, KATO Hirotoshi, YAMADA Shigeru, MIZOE Jun-etsu, TSUJII Hirohiko, Specification of Carbon Ion Dose at the National Institute of Radiological Sciences (NIRS), 10.1269/jrr.48.a81
  57. Dale R G, Dose-rate effects in targeted radiotherapy, 10.1088/0031-9155/41/10/001
  58. Fowler Jack F, Development of radiobiology for oncology—a personal view, 10.1088/0031-9155/51/13/r16
  59. Dale Roger G, Deehan Charles, 7  Brachytherapy, Radiobiological Modelling in Radiation Oncology (2007) ISBN:090574960X p.113-137, 10.1259/9780905749839.chapter07
  60. Webb S, Nahum A E, A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density, 10.1088/0031-9155/38/6/001
  61. Dubray Bernard, Henry-Amar Michel, Meerwaldt Jacobus H., Noordijk Evert M., Dixon Dennis O., Cosset Jean-Marc, Thames Howard D., Radiation-induced lung damage after thoracic irradiation for Hodgkin's disease: the role of fractionation, 10.1016/0167-8140(95)01606-h
  62. Jones Bleddyn, Cárabe-Fernández Alejandro, Dale Roger G, 8  The oxygen effect, Radiobiological Modelling in Radiation Oncology (2007) ISBN:090574960X p.138-157, 10.1259/9780905749839.chapter08
  63. Stewart, Proceedings of the Monte Carlo 2000 Meeting, 285 (2000)